SLN
$22.27
Revenue | $2.1Mn |
Net Profits | $-14.41Mn |
Net Profit Margins | -686.61% |
Silence Therapeutics Plc’s revenue fell -55.95% since last year same period to $2.1Mn in the Q4 2023. On a quarterly growth basis, Silence Therapeutics Plc has generated -24.98% fall in its revenue since last 3-months.
Silence Therapeutics Plc’s net profit fell -4.72% since last year same period to $-14.41Mn in the Q4 2023. On a quarterly growth basis, Silence Therapeutics Plc has generated -74.69% fall in its net profits since last 3-months.
Silence Therapeutics Plc’s net profit margin fell -137.72% since last year same period to -686.61% in the Q4 2023. On a quarterly growth basis, Silence Therapeutics Plc has generated -132.87% fall in its net profit margins since last 3-months.
EPS Estimate Current Quarter | -0.11 |
EPS Estimate Current Year | -0.11 |
Silence Therapeutics Plc’s earning per share (EPS) estimates for the current quarter stand at -0.11 - a -47.04% fall from last quarter’s estimates.
Silence Therapeutics Plc’s earning per share (EPS) estimates for the current year stand at -0.11.
Earning Per Share (EPS) | 0 |
Silence Therapeutics Plc’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2024. This indicates that the Silence Therapeutics Plc has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2024-05-14 | -0.11 | 0 | 100% |